

**Question for written answer E-001321/2023
to the Commission**

Rule 138

Marc Botenga (The Left)

Subject: Auditing of the use of EU funds under COVID-19 vaccine advance purchase agreements

In its answers to my questions E-001820/2022¹ and E-002767/2022² about the Commission's checks on the use of EU funds by pharmaceutical companies received under advance payment agreements, the Commission reiterates that the COVID-19 vaccine advance purchase agreements include checks and audit requirements for the pharmaceutical company up to five years after the contract has been implemented.

Audits may therefore be carried out.

However, the Commission does not specify whether – aside from the 'breakdowns' and documents provided by the companies themselves – it has carried out an audit or requested an independent audit.

1. Other than documents provided by the companies themselves, has the Commission actually carried out an audit of how the funds the companies received were used?
2. If so, when and for which companies?

Submitted: 21.4.2023

¹ https://www.europarl.europa.eu/doceo/document/E-9-2022-001820_EN.html

² https://www.europarl.europa.eu/doceo/document/E-9-2022-002767_EN.html